P2RX3
ENSG00000109991
Target class
Ion channel
Chromosome
11
Approved drugs
2
Clinical candidates (approved and in development)
3
- Approved drugs
- 2
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- Yes
- Other names
- P2X3
- Target name
- P2RX3
- Gene name
- Purinergic receptor P2X 3
- Gene symbol
- P2RX3
- Protein name
- P2X purinoceptor 3 (P2X3) (ATP receptor) (Purinergic receptor)
- Gene biotype
- Protein coding
- Gene family
- Purinergic receptors P2X
- Target class
- Ion channel
- Target type
- Human gene
- Tissues expressed in
- 2
- Highest tissue expression
- 12
- Tissue specificity (Gini)
- 0.919
- Tissue specificity (tau)
- 0.995
- KEGG gene identifiers
- hsa:5024
- Protein interaction confidence
- 0.875526
- Protein interaction partners
- 19
- R-HSA-139853
- R-HSA-418346
- End position
- 57372404
- Start position
- 57338352
- Chromosome
- 11
- Strand
- Forward
- Cell membrane
- Multi-pass membrane protein . Note=Localizes to neuronal cell body of sensory neurons. .
Publication evidence
- PubMed 27626375
- Tissue specificity (tau)
- 0.995
- Expression inequality (Gini)
- 0.918972
Expression in transcripts per million
- Testis
- 12
- Heart - Left Ventricle
- 1.12
- Adrenal Gland
- 0.3
- Liver
- 0.29
- Stomach
- 0.2
Expression in transcripts per million
- Testis12
- Heart - Left Ventricle1.12
- Adrenal Gland0.3
- Liver0.29
- Stomach0.2
- Pituitary0.14
- Colon - Sigmoid0.07
- Small Intestine - Terminal Ileum0.07
- Heart - Atrial Appendage0.06
- Esophagus - Muscularis0.05
- Fallopian Tube0.05
- Adipose - Visceral (Omentum)0.05
- Uterus0.04
- Colon - Transverse0.04
- Thyroid0.04
- Bladder0.04
- Prostate0.04
- Kidney - Medulla0.03
- Nerve - Tibial0.03
- Pancreas0.03
- Brain - Frontal Cortex (BA9)0.03
- Brain - Cortex0.03
- Lung0.03
- Brain - Anterior cingulate cortex (BA24)0.03
- Esophagus - Gastroesophageal Junction0.03
And 29 more, listed on the interactive page.
- GO:0007165
- GO:0055085
- GO:0070207
- GO:0070588
- GO:0071318
- GO:0005886
- GO:0043235
- GO:0001614
- GO:0004931
- GO:0005524
increased urinary sodium excretion
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased urinary sodium excretion
- nervous system
- renal
- immune
PubMed 28216264increased urine excretion
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased urine excretion
- nervous system
- renal
- immune
PubMed 28216264decreased convulsions
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased convulsions
- nervous system
- renal
- immune
PubMed 28216264decreased inflammation
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased inflammation
- nervous system
- renal
- immune
PubMed 28216264hemolysis
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: hemolysis
- nervous system
- renal
- immune
PubMed 28216264increased pain
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased pain
- nervous system
- renal
- immune
PubMed 28216264neurodegeneration
Effects
- Activation/Increase/Upregulation: chronic
Studies
- preclinical: neurodegeneration
- nervous system
- renal
- immune
PubMed 28216264decreased pain
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased pain
- nervous system
- renal
- immune
PubMed 28216264
Related records
Trials (43)
- A 12-Week Study in Participants With Refractory Chronic Cough (MK-7264-012)
- A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
- A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China Extension
- A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
- A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic Cough
- A Dose Escalation Study of Gefapixant (AF-219/MK-7264) in Refractory Chronic Cough (MK-7264-010)
- A Four-Week Multicenter Study Evaluating the Safety and Efficacy of Gefapixant (AF-219/MK-7264) in Subjects With Osteoarthritis of the Knee
- A Multiple-Dose Pharmacokinetics Study of Three Gefapixant (AF-219/MK-7264) Formulations
- A Multiple-Dose Pharmacokinetics Study of Two Gefapixant (AF-219/MK-7264) Formulations
- A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis
- A Study of Camlipixant in Male and Female Healthy Participants and Participants With Hepatic Impairment Aged 18-75 Years of Age
- A Study of Gefapixant (AF-219/MK-7264) in Participants With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
- A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-027)
- A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)
- A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)-China Extension
- A Study of Gefapixant (MK-7264) in Japanese Adult Participants With Refractory or Unexplained Chronic Cough (MK-7264-038)
- A Study to Assess the Effect of Intragastric pH and Fasting on the Pharmacokinetics of Gefapixant (AF-219/MK-7264)
- A Study to Assess the Efficacy of Gefapixant (MK-7264/AF-219), in Participants With Chronic Cough (MK-7264-006)
- A Study to Assess the Tolerability of a Single Dose of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
- A Study to Evaluate the Effect of Gefapixant (AF-219/MK-7264) on Methacholine Hyper-reactivity in Participants With Asthma (MK-7264-009)
Drugs (3)
- Camlipixant P2X purinoceptor 3 antagonist
- Gefapixant P2X purinoceptor 3 antagonist
- Gefapixant citrate P2X purinoceptor 3 antagonist